Article
In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol
2026-07-06
Abstract excerpt
Immunotherapies have become a transformative therapeutic strategy for many cancer types in recent years. Bispecific T-cell engagers (BiTEs) are one promising immunotherapy that enhances cellular antitumour immunity by redirecting T cells towards cancer cells. Recent evidence suggests that BiTE efficacy can be augmented by encoding BiTEs in oncolytic measles virus vectors (MV-BiTE). Infection of cancer cells with M...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 867ffc08-8b7d-5723-98ba-937cb21fcea1
- DOI
- 10.64898/2026.07.02.26357107
